tiprankstipranks
Advertisement
Advertisement

DE:6BG Stock Latest News

Lytix Biopharma Grants 1.23 Million Share Options to Strengthen Executive Incentives
Company AnnouncementsLytix Biopharma Grants 1.23 Million Share Options to Strengthen Executive Incentives
12d ago
6BG
Lytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 2026
PremiumCompany Announcements
Lytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 2026
2M ago
6BG
Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus
PremiumCompany Announcements
Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus
3M ago
6BG
Lytix Biopharma to Present Q1 2026 Results in Investor Webcast
PremiumCompany Announcements
Lytix Biopharma to Present Q1 2026 Results in Investor Webcast
3M ago
6BG
Lytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug
PremiumCompany Announcements
Lytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug
3M ago
6BG
Lytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study
PremiumCompany AnnouncementsLytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study
3M ago
6BG
Lytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma
Premium
Company Announcements
Lytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma
4M ago
6BG
Lytix Biopharma Completes Conversion to Public Limited Company
Premium
Company Announcements
Lytix Biopharma Completes Conversion to Public Limited Company
4M ago
6BG
Lytix Biopharma Overhauls Board and Renews Capital Mandate at AGM
PremiumCompany Announcements
Lytix Biopharma Overhauls Board and Renews Capital Mandate at AGM
4M ago
6BG
Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan
PremiumCompany Announcements
Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan
4M ago
6BG
Lytix Biopharma Appoints New COO to Drive Next Growth Phase
PremiumCompany Announcements
Lytix Biopharma Appoints New COO to Drive Next Growth Phase
4M ago
6BG
Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend
PremiumCompany Announcements
Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend
4M ago
6BG
Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise
PremiumCompany AnnouncementsLytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise
4M ago
6BG
Lytix to Unveil Final Phase II Melanoma Data on Ruxotemitide at AACR 2026
Premium
Company Announcements
Lytix to Unveil Final Phase II Melanoma Data on Ruxotemitide at AACR 2026
5M ago
6BG
Lytix Biopharma Registers Share Capital Increase After NOK 16.3 Million Offering
Premium
Company Announcements
Lytix Biopharma Registers Share Capital Increase After NOK 16.3 Million Offering
5M ago
6BG
Lytix Biopharma’s Oncolytic Peptide Platform Gains Visibility with New JITC Review
PremiumCompany Announcements
Lytix Biopharma’s Oncolytic Peptide Platform Gains Visibility with New JITC Review
6M ago
6BG
Lytix Biopharma Advances Ruxotemitide Program as Strong Phase II Data and Cost Discipline Mark 2025
PremiumCompany Announcements
Lytix Biopharma Advances Ruxotemitide Program as Strong Phase II Data and Cost Discipline Mark 2025
6M ago
6BG
Lytix Biopharma Raises NOK 16.3 Million in Subsequent Share Offering
PremiumCompany Announcements
Lytix Biopharma Raises NOK 16.3 Million in Subsequent Share Offering
6M ago
6BG
Lytix Biopharma’s NOK 30 Million Subsequent Share Offering Closes Today
PremiumCompany Announcements
Lytix Biopharma’s NOK 30 Million Subsequent Share Offering Closes Today
6M ago
6BG
Lytix Biopharma Schedules Webcast for Fourth-Quarter and Second-Half 2025 Results
PremiumCompany AnnouncementsLytix Biopharma Schedules Webcast for Fourth-Quarter and Second-Half 2025 Results
6M ago
6BG
Lytix Biopharma Launches Subsequent Share Offering Following NOK 61 Million Private Placement
Premium
Company Announcements
Lytix Biopharma Launches Subsequent Share Offering Following NOK 61 Million Private Placement
6M ago
6BG
Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company
Premium
Company Announcements
Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company
6M ago
6BG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >